Cargando…

Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment

Breakthrough cancer Pain (BTcP) has a high prevalence in cancer population. Patients with BTcP reported relevant health care costs and poor quality of life. The study assessed the cost-effectiveness of the available Oral Fentanyl Formulations (OFFs) for BTcP in Italy. A decision-analytical model was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortesi, Paolo Angelo, D’Angiolella, Lucia Sara, Vellucci, Renato, Allegri, Massimo, Casale, Giuseppe, Favaretti, Carlo, Kheiraoui, Flavia, Cesana, Giancarlo, Mantovani, Lorenzo Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487011/ https://www.ncbi.nlm.nih.gov/pubmed/28654672 http://dx.doi.org/10.1371/journal.pone.0179523

Ejemplares similares

Assessment and treatment of breakthrough cancer pain: from theory to clinical practice
por: Vellucci, Renato, et al.
Publicado: (2017)

Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis
por: Janknegt, Robert, et al.
Publicado: (2018)

Fentanyl Sublingual Spray for Breakthrough Pain in Cancer Patients
por: Zeppetella, Giovambattista
Publicado: (2013)

Efficiency measures of emergency departments: an Italian systematic literature review
por: Di Laura, Danilo, et al.
Publicado: (2021)

Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
por: Vellucci, R., et al.
Publicado: (2016)

It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer
por: Carlucci, A, et al.
Publicado: (2015)

Keeping CDK18 in balance to prevent DNA replication stress in breast cancer
por: Braams, Esmée, et al.
Publicado: (2018)

Two paths to let the replisome go
por: D'Angiolella, Vincenzo, et al.
Publicado: (2017)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Role of intranasal fentanyl in breakthrough pain management in cancer patients
por: Leppert, Wojciech
Publicado: (2010)

Single-dose fentanyl sublingual spray for breakthrough cancer pain
por: Taylor, Donald R
Publicado: (2013)

Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery
por: Valtola, Antti, et al.
Publicado: (2021)

Prisoners in a pandemic: We should think about detainees during Covid-19 outbreak
por: Tozzo, Pamela, et al.
Publicado: (2020)

E2F1: Cause and Consequence of DNA Replication Stress
por: Fouad, Shahd, et al.
Publicado: (2021)

Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
por: Prommer, Eric, et al.
Publicado: (2012)

Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
por: Darbà, Josep, et al.
Publicado: (2013)

Trick or Treating in Forensics—The Challenge of the Saliva Microbiome: A Narrative Review
por: D’Angiolella, Gabriella, et al.
Publicado: (2020)

Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain
por: Ueberall, Michael A, et al.
Publicado: (2016)

Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment
por: Fouad, Shahd, et al.
Publicado: (2019)

Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain: Pharmacokinetics of Buccal Mucosa Delivery and Clinical Efficacy
por: Darwish, Mona, et al.
Publicado: (2010)

Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets
por: Guitart, Jordi, et al.
Publicado: (2019)

Role for Non-Proteolytic Control of M-phase Promoting Factor Activity at M-phase Exit
por: D'Angiolella, Vincenzo, et al.
Publicado: (2007)

Structural Basis for Recruitment of DAPK1 to the KLHL20 E3 Ligase
por: Chen, Zhuoyao, et al.
Publicado: (2019)

The role of E3 ubiquitin ligases in the development and progression of glioblastoma
por: Humphreys, Luke M., et al.
Publicado: (2021)

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
por: Mercadante, S, et al.
Publicado: (2007)

An Evaluation of Total Disintegration Time for Three Different Doses of Sublingual Fentanyl Tablets in Patients with Breakthrough Pain
por: Nalamachu, Srinivas
Publicado: (2013)

In vitro and in vivo evaluation of a sublingual fentanyl wafer formulation
por: Lim, Stephen CB, et al.
Publicado: (2013)

Skin Microbiome Analysis for Forensic Human Identification: What Do We Know So Far?
por: Tozzo, Pamela, et al.
Publicado: (2020)

A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
por: Freye, Enno
Publicado: (2008)

Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain
por: Skaer, Tracy L
Publicado: (2014)

Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients
por: Poscia, A., et al.
Publicado: (2017)

Breakthroughs and challenges in the management of pediatric viral hepatitis
por: Nicastro, Emanuele, et al.
Publicado: (2021)

5% lidocaine medicated plaster double effect in a case of orofacial localized neuropathic pain
por: Casale, Roberto, et al.
Publicado: (2014)

Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS
por: Masel, Eva Katharina, et al.
Publicado: (2017)

Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study
por: Guitart, Jordi, et al.
Publicado: (2017)

Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
por: Guitart, Jordi, et al.
Publicado: (2018)

Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer
por: Pointreau, Yoann, et al.
Publicado: (2020)

Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study
por: Rauck, R., et al.
Publicado: (2010)

Safety and Efficacy of Oral Transmucosal Fentanyl Citrate Compared to Morphine Sulphate Immediate Release Tablet in Management of Breakthrough Cancer Pain
por: Bhatnagar, Sushma, et al.
Publicado: (2014)

Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
por: Guitart, Jordi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6rhsfe7fvq13jmloivqi2c9qlv